Page 58 - 86_02

2019;84(4):689-706.
26. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotech-
nology: the impact of passive and active targeting in the era of modern
cancer biology. Advanced drug delivery reviews. 2014;66:2-25.
27. Guan LY, Lu Y. New developments in molecular targeted therapy of
ovarian cancer. Discov Med. 2018;26(144):219-29.
28. Gupta A, Kaur CD, Saraf S, Saraf S. Targeting of herbal bioactives
through folate receptors: a novel concept to enhance intracellular drug
delivery in cancer therapy. J Recept Signal Transduct Res.
2017;37(3):314-23.
29. Grada A, Otero-Vinas M, Prieto-Castrillo F, Obagi Z, Falanga V. Rese-
arch Techniques Made Simple: Analysis of Collective Cell Migration
Using the Wound Healing Assay. J Invest Dermatol. 2017;137(2):e11-
e6.
30. Kommineni N, Saka R, Bulbake U, Khan W. Cabazitaxel and thymo-
quinone co-loaded lipospheres as a synergistic combination for breast
cancer. Chemistry and physics of lipids. 2018.
31. Chou TC. Drug combination studies and their synergy quantification
using the Chou-Talalay method. Cancer research. 2010;70(2):440-6.
32. Van Hoesen K, Meynier S, Ribaux P, Petignat P, Delie F, Cohen M. Cir-
culating GRP78 antibodies from ovarian cancer patients: a promising
tool for cancer cell targeting drug delivery system? Oncotarget.
2017;8(63):107176-87.
33. Hernan Perez de la Ossa D, Ligresti A, Gil-Alegre ME, Aberturas MR,
Molpeceres J, Di Marzo V, et al. Poly-epsilon-caprolactone microspheres
as a drug delivery system for cannabinoid administration: development,
characterization and in vitro evaluation of their antitumoral efficacy.
Journal of controlled release : official journal of the Controlled Release
Society. 2012;161(3):927-32.
34. Beaufort CM, Helmijr JC, Piskorz AM, Hoogstraat M, Ruigrok-Ritstier
K, Besselink N, et al. Ovarian cancer cell line panel (OCCP): clinical
importance of in vitro morphological subtypes. PloS one.
2014;9(9):e103988.
35. Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell prolife-
ration via tumor necrosis factor alpha-converting enzyme
(TACE/ADAM17)-mediated transactivation of the epidermal growth fac-
tor receptor. Cancer research. 2004;64(6):1943-50.
36. McKallip RJ, Nagarkatti M, Nagarkatti PS. Delta-9-tetrahydrocanna-
binol enhances breast cancer growth and metastasis by suppression of
the antitumor immune response. Journal of immunology (Baltimore,
Md : 1950). 2005;174(6):3281-9.
37. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis
L, et al. Antitumor activity of plant cannabinoids with emphasis on the
effect of cannabidiol on human breast carcinoma. The Journal of phar-
macology and experimental therapeutics. 2006;318(3):1375-87.
38. Fraguas-Sanchez AI, Fernandez-Carballido A, Torres-Suarez AI. Phyto-
, endo- and synthetic cannabinoids: promising chemotherapeutic
Cannabinoid based chemo-nanotherapy for the treat-
148 ment of gynecological malignancies
Ana I. Fraguas , Ana I. Torres Suárez, et al
An Real Acad Farm Vol. 86. Nº 2 (2020) · pp. 133-150
ANALES
RANF
www.analesranf.com
agents in the treatment of breast and prostate carcinomas. Expert opi-
nion on investigational drugs. 2016;25(11):1311-23.
39. Elbaz M, Nasser MW, Ravi J, Wani NA, Ahirwar DK, Zhao H, et al. Mo-
dulation of the tumor microenvironment and inhibition of EGF/EGFR
pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer.
Molecular oncology. 2015;9(4):906-19.
40. Ramer R, Merkord J, Rohde H, Hinz B. Cannabidiol inhibits cancer cell
invasion via upregulation of tissue inhibitor of matrix metalloprotei-
nases-1. Biochemical pharmacology. 2010;79(7):955-66.
41. Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D. Cannabidiol in-
hibits human glioma cell migration through a cannabinoid receptor-
independent mechanism. British journal of pharmacology.
2005;144(8):1032-6.
42. Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H, Wal-
ker EA. Cannabidiol inhibits paclitaxel-induced neuropathic pain
through 5-HT(1A) receptors without diminishing nervous system func-
tion or chemotherapy efficacy. British journal of pharmacology.
2014;171(3):636-45.
43. Ward SJ, Ramirez MD, Neelakantan H, Walker EA. Cannabidiol pre-
vents the development of cold and mechanical allodynia in paclitaxel-
treated female C57Bl6 mice. Anesthesia and analgesia.
2011;113(4):947-50.
44. King KM, Myers AM, Soroka-Monzo AJ, Tuma RF, Tallarida RJ, Walker
EA, et al. Single and combined effects of Delta(9) -tetrahydrocanna-
binol and cannabidiol in a mouse model of chemotherapy-induced
neuropathic pain. British journal of pharmacology.
2017;174(17):2832-41.
45. Miyato H, Kitayama J, Yamashita H, Souma D, Asakage M, Yamada
J, et al. Pharmacological synergism between cannabinoids and pacli-
taxel in gastric cancer cell lines. J Surg Res. 2009;155(1):40-7.
46. Fouad AA, Albuali WH, Al-Mulhim AS, Jresat I. Cardioprotective effect
of cannabidiol in rats exposed to doxorubicin toxicity. Environmental
toxicology and pharmacology. 2013;36(2):347-57.
47. Hao E, Mukhopadhyay P, Cao Z, Erdelyi K, Holovac E, Liaudet L, et al.
Cannabidiol Protects against Doxorubicin-Induced Cardiomyopathy by
Modulating Mitochondrial Function and Biogenesis. Molecular medicine
(Cambridge, Mass). 2015;21:38-45.
48. Ribatti D. The chick embryo chorioallantoic membrane (CAM) assay.
Reproductive toxicology (Elmsford, NY). 2017;70:97-101.
49. Lokman NA, Elder AS, Ricciardelli C, Oehler MK. Chick chorioallantoic
membrane (CAM) assay as an in vivo model to study the effect of newly
identified molecules on ovarian cancer invasion and metastasis. Int J
Mol Sci. 2012;13(8):9959-70.
50. Vu BT, Shahin SA, Croissant J, Fatieiev Y, Matsumoto K, Le-Hoang
Doan T, et al. Chick chorioallantoic membrane assay as an in vivo
model to study the effect of nanoparticle-based anticancer drugs in
ovarian cancer. Scientific reports. 2018;8(1):8524.